tetano
Editor, Senior Moderator
Ann Thorac Med
. Jan-Mar 2022;17(1):1-13.
doi: 10.4103/atm.atm_404_21. Epub 2022 Jan 14.
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review
Malay Sarkar[SUP] 1 [/SUP], Irappa V Madabhavi[SUP] 2 3 [/SUP], Pham Nguyen Quy[SUP] 4 [/SUP], Manjunath B Govindagoudar[SUP] 5 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus responsible for the pandemic coronavirus disease 19 (COVID-19). It has significant impact on human health and public safety along with negative social and economic consequences. Vaccination against SARS-CoV-2 is likely the most effective approach to sustainably control the global COVID-19 pandemic. Vaccination is highly effective in reducing the risk of severe COVID-19 disease. Mass-scale vaccination will help us in attaining herd immunity and will lessen the negative impact of the disease on public health, social and economic conditions. The present pandemic stimulated the development of several effective vaccines based on different platforms. Although the vaccine is safe and efficacious, rare cases of thrombosis and thrombocytopenia following the use of vaccination with the ChAdOx1 CoV-19 vaccine (AstraZeneca, University of Oxford, and Serum Institute of India) or the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) have been reported globally. This review focussed on the definition, epidemiology, pathogenesis, clinical features, diagnosis, and management of vaccine associated thrombosis.
Keywords: COVID-19 vaccine; heparin-induced thrombocytopenia; platelet factor-4; thrombosis; vaccine-induced immune thrombotic thrombocytopenia.
. Jan-Mar 2022;17(1):1-13.
doi: 10.4103/atm.atm_404_21. Epub 2022 Jan 14.
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review
Malay Sarkar[SUP] 1 [/SUP], Irappa V Madabhavi[SUP] 2 3 [/SUP], Pham Nguyen Quy[SUP] 4 [/SUP], Manjunath B Govindagoudar[SUP] 5 [/SUP]
Affiliations
- PMID: 35198043
- PMCID: PMC8809131
- DOI: 10.4103/atm.atm_404_21
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus responsible for the pandemic coronavirus disease 19 (COVID-19). It has significant impact on human health and public safety along with negative social and economic consequences. Vaccination against SARS-CoV-2 is likely the most effective approach to sustainably control the global COVID-19 pandemic. Vaccination is highly effective in reducing the risk of severe COVID-19 disease. Mass-scale vaccination will help us in attaining herd immunity and will lessen the negative impact of the disease on public health, social and economic conditions. The present pandemic stimulated the development of several effective vaccines based on different platforms. Although the vaccine is safe and efficacious, rare cases of thrombosis and thrombocytopenia following the use of vaccination with the ChAdOx1 CoV-19 vaccine (AstraZeneca, University of Oxford, and Serum Institute of India) or the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) have been reported globally. This review focussed on the definition, epidemiology, pathogenesis, clinical features, diagnosis, and management of vaccine associated thrombosis.
Keywords: COVID-19 vaccine; heparin-induced thrombocytopenia; platelet factor-4; thrombosis; vaccine-induced immune thrombotic thrombocytopenia.